{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/05/13/3293817/0/en/Zenas-BioPharma-Announces-First-Subject-Dosed-in-Phase-1-Clinical-Trial-of-ZB021-a-Novel-Potentially-Best-in-Class-Oral-IL-17AA-AF-Inhibitor.html", "message": "News view counter 722450 successfully enlarged"}